SG11201407591PA - Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof - Google Patents

Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof

Info

Publication number
SG11201407591PA
SG11201407591PA SG11201407591PA SG11201407591PA SG11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA SG 11201407591P A SG11201407591P A SG 11201407591PA
Authority
SG
Singapore
Prior art keywords
genentech
california
south san
international
san francisco
Prior art date
Application number
SG11201407591PA
Other languages
English (en)
Inventor
Srinivasan Babu
Francis Gosselin
Yingqing Ran
Travis Remarchuk
Scott J Savage
Jeffrey Stults
Herbert Yajima
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201407591PA publication Critical patent/SG11201407591PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165Heterorings having nitrogen atoms as the only ring heteroatoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201407591PA 2012-05-17 2013-05-17 Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof SG11201407591PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648535P 2012-05-17 2012-05-17
PCT/US2013/041695 WO2013173784A1 (fr) 2012-05-17 2013-05-17 Procédé de fabrication de composés de cyclopentapyrimidine hydroxylée et sels de ceux-ci

Publications (1)

Publication Number Publication Date
SG11201407591PA true SG11201407591PA (en) 2015-01-29

Family

ID=48534508

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407591PA SG11201407591PA (en) 2012-05-17 2013-05-17 Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof

Country Status (18)

Country Link
US (1) US9315471B2 (fr)
EP (1) EP2850200A1 (fr)
JP (1) JP6355625B2 (fr)
KR (1) KR102123131B1 (fr)
CN (1) CN104471070B (fr)
AU (1) AU2013262521B2 (fr)
BR (1) BR112014028573B1 (fr)
CA (1) CA2873661C (fr)
HK (1) HK1208500A1 (fr)
IL (1) IL235699B (fr)
MA (1) MA37647A1 (fr)
MX (1) MX354373B (fr)
MY (1) MY169029A (fr)
NZ (1) NZ702950A (fr)
RU (1) RU2642311C2 (fr)
SG (1) SG11201407591PA (fr)
WO (1) WO2013173784A1 (fr)
ZA (1) ZA201409226B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104487430B (zh) 2012-05-17 2016-08-24 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
CN104470913B (zh) 2012-05-17 2018-07-20 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
TR201807444T4 (tr) 2012-05-17 2018-06-21 Genentech Inc Amino asit bileşiklerini hazırlama prosesi.
PE20150725A1 (es) 2012-05-17 2015-05-17 Genentech Inc Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este
EP4282973A3 (fr) * 2013-11-15 2024-03-27 F. Hoffmann-La Roche AG Procédés de préparation pour dérivés de pyrmidinecyclopentane
BR112017005931B1 (pt) * 2014-09-26 2024-04-30 F. Hoffmann-La Roche Ag Processos para preparar um composto de ciclopentil[d]pirimidin-4-il) piperazina e composto de ciclopentil[d]pirimidin-4-il)piperazina
JP6875501B2 (ja) 2016-08-10 2021-05-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Aktプロテインキナーゼ阻害剤を含む薬学的組成物
WO2018035249A1 (fr) * 2016-08-16 2018-02-22 Imago Biosciences, Inc. Compositions et procédés de production d'aminocyclopropanes stéréoisomériquement purs
WO2019122421A1 (fr) * 2017-12-22 2019-06-27 Astrazeneca Ab Réduction stéréosélective de cétone à l'aide d'une enzyme cétoréductase
CA3186562A1 (fr) * 2020-07-22 2022-01-27 Jian Wu Sel et forme cristalline de derive de dihydropyrido[2,3-d]pyrimidine
WO2023043869A1 (fr) 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de citrate d'ipatasertib

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178829A1 (fr) 1993-12-12 1995-06-15 Yigal Cohen Nouveau procede servant a proteger des vegetaux des infections fongiques
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0918090A3 (fr) 1997-11-04 2002-08-28 Eli Lilly And Company Cétoreductase gène et protéine de levure
EP0982300A3 (fr) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
US6376496B1 (en) 1999-03-03 2002-04-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
DE10119274A1 (de) 2001-04-20 2002-10-31 Juelich Enzyme Products Gmbh Enzymatisches Verfahren zur enantioselektiven Reduktion von Ketoverbindungen
JP4550811B2 (ja) 2003-06-09 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング パピローマウイルスのインヒビター
CA2610888C (fr) * 2005-06-10 2011-02-08 Merck & Co., Inc. Inhibiteurs de l'activite akt
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2009036404A2 (fr) * 2007-09-13 2009-03-19 Codexis, Inc. Polypeptides de cétoréductase pour la réduction d'acétophénones
WO2009047255A1 (fr) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine
AU2009204019B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
EP2419404B1 (fr) 2009-04-15 2015-11-04 AbbVie Inc. Composes anti virale
CA2778291C (fr) 2009-10-23 2014-02-11 Eli Lilly And Company Inhibiteurs d'akt
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
TR201807444T4 (tr) 2012-05-17 2018-06-21 Genentech Inc Amino asit bileşiklerini hazırlama prosesi.
CN104470913B (zh) 2012-05-17 2018-07-20 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
CN104487430B (zh) 2012-05-17 2016-08-24 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
WO2014071194A2 (fr) 2012-11-01 2014-05-08 Katz Robert S Méthodes de traitement de la fibromyalgie
WO2014127350A1 (fr) 2013-02-18 2014-08-21 The Scripps Research Institute Modulateurs des récepteurs de la vasopressine à pouvoir thérapeutique
US10131637B2 (en) 2013-03-15 2018-11-20 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
US9315471B2 (en) 2016-04-19
IL235699B (en) 2018-12-31
KR20150018579A (ko) 2015-02-23
BR112014028573B1 (pt) 2021-11-16
MA37647A1 (fr) 2016-03-31
RU2014151014A (ru) 2016-07-10
ZA201409226B (en) 2017-09-27
AU2013262521B2 (en) 2017-03-02
MX354373B (es) 2018-02-28
BR112014028573A2 (pt) 2018-04-24
CN104471070B (zh) 2018-09-25
CA2873661A1 (fr) 2013-11-21
IL235699A0 (en) 2015-01-29
KR102123131B1 (ko) 2020-06-15
HK1208500A1 (en) 2016-03-04
MX2014013855A (es) 2016-03-21
AU2013262521A1 (en) 2015-01-22
RU2642311C2 (ru) 2018-01-24
EP2850200A1 (fr) 2015-03-25
CN104471070A (zh) 2015-03-25
NZ702950A (en) 2016-09-30
JP6355625B2 (ja) 2018-07-11
WO2013173784A1 (fr) 2013-11-21
MY169029A (en) 2019-02-04
CA2873661C (fr) 2020-07-21
JP2015518715A (ja) 2015-07-06
US20150099880A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
SG11201407591PA (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201408271VA (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201403402VA (en) Compounds
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201407613RA (en) Process for making hydroxylated cyclopentylpyrimidine compounds
SG11201408094YA (en) Neprilysin inhibitors
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201407618VA (en) Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201406973PA (en) Complement pathway modulators and uses thereof